Lifelong, Resistance-Proof Antivirals

State-of-the-art antivirals are static biological or chemical compounds. The problem is that these static interventions are used to treat viral pathogens that (unpredictably) evolve across patients and populations. As a result, new antivirals (e.g., annual flu vaccines) must continually be developed each time a viral pathogen evolves resistance to a current antiviral.

Our goal is to develop the first antivirals that evolve along with mutating viral infections—to confer lifelong, ‘resistance-proof’ control. Imagine taking an influenza drug once and never worrying about any flu variant again in your life.